MedPath

Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery

Active, not recruiting
Conditions
Breast Neoplasms
Germline BRCA1 Gene Mutation
Germline Mutation Abnormality
Germline BRCA2 Gene Mutation
Benign Breast Disease
Registration Number
NCT04585074
Lead Sponsor
Severance Hospital
Brief Summary

Robotic mastectomy and immediate reconstruction have been introduced in 2015. However, since robotic mastectomy is the latest surgical technique, there is a lack of studies prospectively comparing conventional mastectomy and immediate reconstruction with robotic mastectomy. For this reason, this study is designed to establish a single institution cohort study that prospectively collects patients undergoing mastectomy and reconstruction. This study was initially designed as a single institution study, however, currently, the study was extended to the multicenter study including 18 institutions over the country. Using the established prospective cohort data, a comparative study of robotic mastectomy with conventional mastectomy and reconstruction, and cost-effectiveness and satisfaction of robotic endoscopic surgery, and cost-effectiveness and satisfaction of reconstructive surgery are to be analyzed.

Detailed Description

This study is a multi-institution cohort study that prospectively collects patients undergoing mastectomy and reconstruction.

Patients' inclusion criteria is as below; adult women between the ages of 19 and 80, with breast cancer or high risk of breast cancer (patients with a BRCA1/2 mutation, TP53 mutation, PALB2 mutation, etc) scheduled for therapeutic or prophylactic mastectomy, and want immediate reconstruction.

Patients planned for breast-conserving surgery or who do not want immediate reconstruction will be excluded. Patients who planned for surgery on both sides in the different methods (e.g. right for RNSM and left for conventional open NSM) are also excluded. Meanwhile, cases with ipsilateral NSM and contralateral partial mastectomy or excision are included.

The goal number of enrolled patients is 2000.

Collecting data includes patients' clinicopathological factors including height, weight, etc. And also collecting surgical results, oncological results, cost-effectiveness, and satisfactions of patients to secure high-level data.

The satisfaction of patients using the Breast Q survey, basic characteristics like height, weight, etc, and patients' photos will be collected preoperatively.

Also, patients' data will be collected within 6 months after surgery including clinical-pathological factors, surgery results (drainage amount, removal date, complications), postoperative recovery evaluation, complications and adverse reactions, cost, etc.

Between 6 months and 1 year(Patients who have undergone skin sparing mastectomy can do within up to 3 years) after surgery, the results of surgery, recurrence, satisfaction survey, and postoperative photos will be collected.

Every 12 months thereafter, whether adjuvant therapy (chemotherapy, radiation therapy, targeted therapy, endocrine therapy) was implemented, surgical results, and recurrence will be investigated and collected until the end of the study period.

An interim analysis will be done after completing the recruitment of subjects by the 4th year after the start of the study and collecting data. Complete the follow-up observation and data collection of the subjects recruited in the 5-9 years and the final analysis will be conducted.

Categorial variables will be examined by the chi-square test or Fisher's exact test.

Continuous variables will be examined by t-test or ANOVA, and M-W test or K-W test if needed.

Survival analysis will be examined by Kaplan-Meier plot and log-rank test.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Female
Target Recruitment
2000
Inclusion Criteria
  • Female patient between the ages of 19 and 80
  • Patients with breast cancer or high risk of breast cancer ( BRCA1/2 mutation, TP53 mutation, PALB2, etc.)
  • Patients scheduled for therapeutic or prophylactic mastectomy (including conventional mastectomy, skin sparing mastectomy, areolar conserving mastectomy)
  • Patients who want immediate reconstruction during mastectomy
  • Those agreed in writing consent to participate study
Exclusion Criteria
  • Patients scheduled for breast conserving mastectomy
  • Patients who do not want immediate reconstruction during mastectomy
  • Patients who planned for surgery on both sides in the different methods

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Postoperative complication rates in 30 daysPostoperative 30 days

Postoperative complication rates are calculated as total number of postoperative complication cases per total operation cases.

Clavien-Dindo grade of postoperative complicationsPostoperative 180 days

Clavien-Dindo grade of postoperative complications is evaluated. The highest grade of postoperative complications are used for the analysis.

Secondary Outcome Measures
NameTimeMethod
Patient's satisfaction (about reconstruction expectations)within preoperative 4 weeks to operation and within postoperative 6 month to 12 month.(Patients who have undergone skin sparing mastectomy can do within up to 3 years)

Reconstruction Expectations of Preoperative Short Form. In all scales, higher scores reflect a better outcome.

Surgeon's satisfactionPostoperative 6 month to 12 month(Patients who have undergone skin sparing mastectomy can do within up to 3 years

Satisfaction of Surgery assessed by (Plastic)Surgeon(s) Items(1), Response Options(Overall symmetry, postoperative scar, nipple areolar complex symmetry, etc), Range(0-10) The higher scores are, the better an outcome is.

Cost-effectivenessPostoperative 6 month to 1 year(Patients who have undergone skin sparing mastectomy can do within up to 3 years

Cost-effectiveness evaluation according to the surgical method, by conducting a questionnaire survey on the subject 6 months to 1 year(Patients who have undergone skin sparing mastectomy up to 3 years) after the last surgery. Evaluation follows the EuroQol five-dimension scale(EQ5D, EQ5D-5L) Korean version questionnaire. In all scales, higher scores reflect a better outcome.

Recurrence free survival (RFS)Postoperative 5 years

Events of RFS includes locoregional recurrence, distant recurrence, and death. Contralateral breast cancer and second primary malignancy are considered to be censored data.

Cancer incidence ratePostoperative 5 years

cancer incidence rate for those underwent prophylactic mastectomy

Patient's satisfaction (about reconstruction results)within preoperative 4 weeks to operation and within postoperative 6 month to 12 month.(Patients who have undergone skin sparing mastectomy can do within up to 3 years)

1. Mastectomy Module Pre-and Postoperative Scales Satisfaction with Breasts as assessed by BREAST-Q version 2.0. Higher scores reflect a better outcome.

2. Reconstruction Module Pre-and Postoperative Scales Satisfaction with abdomen as assessed by BREAST-Q version 2.0 (This scale should only be completed by the patient who has had reconstruction using a transverse rectus abdominis myocutaneous flap(TRAM flap) or deep inferior epigastric perforators flap(DIEP flap). Otherwise, skip it.) Satisfaction with Back as assessed by BREAST-Q version 2.0 (This scale should only be completed by the patient who has had reconstruction using a latissimus dorsi flap. Otherwise, skip it.) Satisfaction with Implants as assessed by BREAST-Q version 2.0 (This scale should only be completed by the patient who has had reconstruction using implants. Otherwise, skip it.) In all scales, higher scores reflect a better outcome.

Trial Locations

Locations (18)

Chungnam National University Sejong Hospital

🇰🇷

Sejong, Chungcheongnam-do, Korea, Republic of

Wonju Severance Christian hospital

🇰🇷

Wonju, Gangwon-do, Korea, Republic of

Korea University Ansan Hospital

🇰🇷

Ansan, Gyeonggi-do, Korea, Republic of

Myongji Hospital

🇰🇷

Goyang, Gyeonggi-do, Korea, Republic of

Yongin Severance Hospital

🇰🇷

Yongin-si, Gyeonggi-do, Korea, Republic of

Samsung Changwon Medical Center

🇰🇷

Changwon, Gyeongsangnam-do, Korea, Republic of

Kyungpook National University Chilgok Hospital

🇰🇷

Daegu, Korea, Republic of

Gangnam Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul Metropolitan Government Seoul National University Boramae Medical Center

🇰🇷

Seoul, Korea, Republic of

Korea University Guro Hospital

🇰🇷

Seoul, Korea, Republic of

Yonsei University College of Medicine

🇰🇷

Seoul, Korea, Republic of

Kosin University Gospel Hospital

🇰🇷

Busan, Korea, Republic of

Soonchunhyang University Hospital

🇰🇷

Seoul, Korea, Republic of

The Catholic University of Korea, Incheon ST. Mary's Hospital

🇰🇷

Incheon, Korea, Republic of

Korea University Anam Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath